



Sustiva® (efavirenz) – New Warning

- On August 31, 2016, the [FDA approved](#) a new update to the *Warnings and Precautions* section of the [Sustiva \(efavirenz\)](#) drug label, regarding QTc interval prolongation.
- Sustiva is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
- The effect of Sustiva on the QTc interval was evaluated in an open-label, placebo-controlled study in 58 healthy subjects enriched for CYP2B6 polymorphisms.
 - A positive relationship between Sustiva concentration and QTc prolongation was observed.
- Alternatives to Sustiva should be considered when co-administered with a drug with a known risk of torsade de pointes or when administered to patients at higher risk of torsade de pointes.
- Other warnings and precautions of Sustiva include drug interactions, resistance, co-administration with related products, psychiatric symptoms, nervous system symptoms, embryo-fetal toxicity, rash, hepatotoxicity, convulsions, lipid elevations, immune reconstitution syndrome, and fat redistribution.
- In addition, the Sustiva drug label has been updated with information regarding interactions with QT prolonging drugs and other classes of drugs, and the *Clinical Pharmacology* section has been updated with details about Sustiva's effects on cardiac electrophysiology.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.